Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD4E9T
|
|||
| Drug Name |
CSL346
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diabetic kidney disease [ICD-11: GB61.Z] | Phase 2 | [1] | |
| Company |
CSL Behring
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor B (VEGFB) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathway Interaction Database | VEGFR1 specific signals | |||
| Reactome | Platelet degranulation | |||
| VEGF ligand-receptor interactions | ||||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04419467) A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.